Skip to main content

Overall Survival Improved for Contemporary Patients with Melanoma: A 2004-2015 National Cancer Database Analysis.

Publication ,  Journal Article
Farrow, NE; Turner, MC; Salama, AKS; Beasley, GM
Published in: Oncol Ther
December 2020

INTRODUCTION: Since 2011, encouraging clinical trial results have led to approval of multiple new therapies for advanced melanoma, but the impact of these therapies outside of trial populations is largely unknown. This study examines use of novel therapies and survival in contemporary patients with melanoma. METHODS: Stage I-IV melanoma patients were identified in the 2004-2015 National Cancer Database and grouped into historic (2004-2010) and contemporary (2011-2015) cohorts. Overall survival (OS) was compared using Kaplan-Meier and Cox proportional hazard modeling adjusting for patient, tumor, and facility characteristics. RESULTS: Of 268,668 patients, 136,828 were classified as historic and 131,840 as contemporary. Among all stages, immunotherapy utilization was significantly higher among contemporary patients (5.3% vs. 5.1%, p = 0.006). Adjusted OS was improved in the contemporary cohort (hazard ratio [HR]: 0.90 p < 0.001). There was no difference in OS among stage I/II patients between groups (HR: 0.99, p = 0.63), while OS was significantly improved for contemporary stage III/IV patients (HR: 0.85, p < 0.001). Among stage III/IV patients who received immunotherapy, OS was improved for the contemporary cohort (HR: 0.87, p = 0.014). CONCLUSIONS: Adjusted overall survival for contemporary melanoma patients is improved. This effect is driven by improvements for those with advanced stage disease, particularly those that received immunotherapy and BRAF/MEK targeted therapies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Oncol Ther

DOI

EISSN

2366-1089

Publication Date

December 2020

Volume

8

Issue

2

Start / End Page

261 / 275

Location

New Zealand

Related Subject Headings

  • 4206 Public health
  • 4202 Epidemiology
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Farrow, N. E., Turner, M. C., Salama, A. K. S., & Beasley, G. M. (2020). Overall Survival Improved for Contemporary Patients with Melanoma: A 2004-2015 National Cancer Database Analysis. Oncol Ther, 8(2), 261–275. https://doi.org/10.1007/s40487-020-00117-1
Farrow, Norma E., Megan C. Turner, April K. S. Salama, and Georgia M. Beasley. “Overall Survival Improved for Contemporary Patients with Melanoma: A 2004-2015 National Cancer Database Analysis.Oncol Ther 8, no. 2 (December 2020): 261–75. https://doi.org/10.1007/s40487-020-00117-1.
Farrow NE, Turner MC, Salama AKS, Beasley GM. Overall Survival Improved for Contemporary Patients with Melanoma: A 2004-2015 National Cancer Database Analysis. Oncol Ther. 2020 Dec;8(2):261–75.
Farrow, Norma E., et al. “Overall Survival Improved for Contemporary Patients with Melanoma: A 2004-2015 National Cancer Database Analysis.Oncol Ther, vol. 8, no. 2, Dec. 2020, pp. 261–75. Pubmed, doi:10.1007/s40487-020-00117-1.
Farrow NE, Turner MC, Salama AKS, Beasley GM. Overall Survival Improved for Contemporary Patients with Melanoma: A 2004-2015 National Cancer Database Analysis. Oncol Ther. 2020 Dec;8(2):261–275.

Published In

Oncol Ther

DOI

EISSN

2366-1089

Publication Date

December 2020

Volume

8

Issue

2

Start / End Page

261 / 275

Location

New Zealand

Related Subject Headings

  • 4206 Public health
  • 4202 Epidemiology
  • 3211 Oncology and carcinogenesis